Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Snap Stock Will Make a Strong Recovery Sooner Than You Think

By Chris Lau, InvestorPlace Contributor

SNAP stock is on fire for two good reasons: an analyst upgrade and a strong Q4 report, making it possible for a longer-term comeback.

Sage Stock Pops on FDA Approval for Postpartum Depression Drug

By Chris Lau, InvestorPlace Contributor

Sage stock is up after the FDA approved its Zulresso, the first ever drug specifically for postpartum depression.

7 Financial Stocks to Invest In Today

By Chris Lau, InvestorPlace Contributor

With the easy money already made and rate hikes slowing in 2019, financial stocks will see moderately good results in the months ahead.

Why NIO Is Not the Tesla of China

By Chris Lau, InvestorPlace Contributor

Despite the large, recent decline of NIO stock, NIO has multiple, upcoming positive catalysts that should boost NIO stock price.

Nike Might Blast Higher After Its Earnings Report

By Chris Lau, InvestorPlace Contributor

Bears are betting against Nike stock ahead of its earnings report. This is despite its digital transformation accelerating growth.

Load More